Abstract
Previous studies demonstrated that some pyrazole derivatives could be considered as potential anticancer agents. A series of 1,3,5-triaryl-1H-pyrazole derivatives were prepared by the reaction of phenylhydrazin and different chalcones. The previous classic synthesis method was developed for a simpler procedure. The cytotoxicity of these compounds was determined against three cancer cell lines (HT-29), (MCF-7), (AGS) as well as fibroblastic cell line (NIH-3T3) using MTT assay. These biological studies proved that 5f and 5l were the most potent compounds in this series. Furthermore, 5f showed a partial selectivity in cytotoxicity effect between the cancerous and normal cell lines.
Keywords: Tri-arylpyrazole, cytotoxicity, synthesis, HT-29, MCF-7, AGS.
Letters in Drug Design & Discovery
Title:Synthesis and Anticancer Activity of 1, 3, 5-Triaryl-1H-Pyrazole
Volume: 12 Issue: 9
Author(s): Sajad Ghadbeigi, Seyed Nasser Ostad, Abbas Shafiee and Mohsen Amini
Affiliation:
Keywords: Tri-arylpyrazole, cytotoxicity, synthesis, HT-29, MCF-7, AGS.
Abstract: Previous studies demonstrated that some pyrazole derivatives could be considered as potential anticancer agents. A series of 1,3,5-triaryl-1H-pyrazole derivatives were prepared by the reaction of phenylhydrazin and different chalcones. The previous classic synthesis method was developed for a simpler procedure. The cytotoxicity of these compounds was determined against three cancer cell lines (HT-29), (MCF-7), (AGS) as well as fibroblastic cell line (NIH-3T3) using MTT assay. These biological studies proved that 5f and 5l were the most potent compounds in this series. Furthermore, 5f showed a partial selectivity in cytotoxicity effect between the cancerous and normal cell lines.
Export Options
About this article
Cite this article as:
Ghadbeigi Sajad, Nasser Ostad Seyed, Shafiee Abbas and Amini Mohsen, Synthesis and Anticancer Activity of 1, 3, 5-Triaryl-1H-Pyrazole, Letters in Drug Design & Discovery 2015; 12 (9) . https://dx.doi.org/10.2174/1570180812666150326004723
DOI https://dx.doi.org/10.2174/1570180812666150326004723 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular and Genetic Bases of Pancreatic Cancer
Current Drug Targets Nanotechnology: Nanomedicine, Nanotoxicity and Future Challenges
Nanoscience & Nanotechnology-Asia NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions
Current Angiogenesis (Discontinued) Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics New Developments and Prospective Applications for β (1,3) Glucans
Recent Patents on Biotechnology Predicting Chemotherapy Sensitivity Profiles for Breast Cancer Cell Lines with and Without Stem Cell-Like Features
Current Signal Transduction Therapy NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets α-Methylene-γ-lactones as a Novel Class of Anti-leukemic Agents
Anti-Cancer Agents in Medicinal Chemistry The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Future of Protease Activity Assays
Current Pharmaceutical Design Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry